Avalyn Pharma adds Robert Meyer, M.D. to board of directors

Avalyn Pharma Inc. disclosed in an 8-K that on September 15, 2026, its board added Robert Meyer, M.D. as a new director. The appointment came upon recommendation of the board's Nominating and Corporate Governance Committee, placing Dr. Meyer as a Class II director with a term running until the 2028 annual stockholders meeting.¹ The board found him independent under Nasdaq's listing standards.¹

Dr. Meyer's background spans industry, academia, and government. Between January 2018 and October 2024, he worked as a principal on the Drug and Biologic Products team at Greenleaf Health Inc., an FDA-focused consulting firm later acquired by Eliquent Life Sciences.¹ Earlier, from March 2013 to December 2017, he held an associate professor post in Public Health Sciences at the University of Virginia School of Medicine, also directing the Virginia Center for Translational and Regulatory Sciences.¹ Before that, he spent time at Merck starting in October 2007, rising to Vice President and Head of Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories, a role he held from late 2009 into early 2013.¹ His FDA tenure ran from 1994 to 2007, including stints leading the Division of Pulmonary and Allergy Drug Products in the late 1990s and early 2000s, followed by leadership of the Office of Drug Evaluation II within the Center for Drug Evaluation and Research through 2007.¹

He has also served on the boards of Chimerix (acquired by Jazz Pharmaceuticals), Translate Bio (acquired by Sanofi), and Correvio Pharma.¹

Under Avalyn's compensation policy, Dr. Meyer qualifies for a $40,000 annual retainer and received an option grant for 31,182 shares of common stock upon joining.¹ That initial grant vests in equal installments over three years.¹